The compositions and methods of administration described in this invention are based on indole carbazole, which causes terminal differentiation of tumor cells by exploiting a normal physiologic pathway.

Toxic drugs used to treat epithelial cancers often kill both normal and tumorous cells whereas retinoids used to prevent tumor formation appear to have a suppressive rather than a curative effect. The compositions and methods of administration described in this invention are based on indole carbazole, which causes terminal differentiation of tumor cells by exploiting a normal physiologic pathway. They can be used to regress as well as prevent skin tumors.

U.S. Patent No. 7,056,908 issued 06 Jun 2006 (HHS Reference No. E-014- 1991/0-US-08)

Inventors: Stuart H. Yuspa et al. (NCI)

Licensees sought. In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.